ABSTRACT
Objective To examine and compare the prevalence, incidence, and specificity and positive predictive value of incidence measures in a national commercial insurance database and a state Medicaid database, for different age groups over the life span.
Methods This cross-sectional study examined the annual prevalence of schizophrenia in 2019 in two databases: a) MarketScan, a United States national commercial insurance database (N = 16,365,997), and b) New York State Medicaid program (N = 4,414,153). A subset of these individuals with 10 years of continuous insurance prior to 2019 (2009-2018) was used to assess incidence and to create a reference standard for incidence measure testing, including positive predictive value and specificity, by age group. Continuous enrollment was required for all years of study (45-day gap allowance per year, and one or more health care services annually to ensure opportunity to be diagnosed).
Results The prevalence of schizophrenia in 2019 was 0.13% in MarketScan, and 2.13% in Medicaid. Prevalence was highest in MarketScan among individuals aged 21-25 years. In contrast, prevalence in Medicaid increased over the lifespan, with the peak among those 56-60 years of age. The incidence of new-onset schizophrenia in 2019 was 0.07% in MarketScan and 0.19% in Medicaid and peaked in young adulthood (26-30 years of age) in both databases (0.16% and 0.40%, respectively). Positive predictive value (PPV) for the incidence measures was higher for women than men and increased with longer lookback periods prior to the first schizophrenia diagnosis in 2019. Using a one-year lookback period, the PPV for those ≤35 years of age was 79% in MarketScan and 51% in Medicaid; a ≥95% PPV was achieved with a two-year lookback in MarketScan, and a seven-year lookback period in Medicaid. PPVs were also higher in younger age groups; in Medicaid a two-year lookback period yielded a PPV of 68% for those ≤35 years, but was 94% for those ≤20 years. Specificity was high even for the total population with one year of observation prior to the first schizophrenia diagnosis in 2019, and was higher in Medicaid (92%) than in MarketScan (80%), increasing further with longer lookback periods in both databases.
Conclusions The prevalence of schizophrenia is over 10-fold higher, and the incidence two-fold higher, in the New York State Medicaid population compared to the MarketScan national commercial insurance database. Within each database, prevalence and incidence varied by sex, age, and duration of insurance. Yet despite these differences, accurate measures of incidence of new-onset schizophrenia could be constructed with high specificity and positive predictive values.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Nathan Kline Institute for Psychiatric Research IRB The University of Chicago IRB
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: No external funding was utilized for this study.
Conflicts: All authors report no conflicts of interest specifically related to this work.
This revision has been updated to include Shalmali Joshi and Noemie Elhadad as co-authors.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
